Affiliation:
1. Howard Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA
2. Department of Biology and Chemistry, Nyack College, Nyack, New York, USA
Abstract
ABSTRACT
Multidrug-resistant (MDR) tuberculosis, defined as tuberculosis resistant to the two first-line drugs isoniazid and rifampin, poses a serious problem for global tuberculosis control strategies. Lack of a safe and convenient model organism hampers progress in combating the spread of MDR strains of
Mycobacterium tuberculosis
. We reasoned that auxotrophic MDR mutants of
M. tuberculosis
would provide a safe means for studying MDR
M. tuberculosis
without the need for a biosafety level 3 (BSL3) laboratory. Two different sets of triple auxotrophic mutants of
M. tuberculosis
were generated, which were auxotrophic for the nutrients leucine, pantothenate, and arginine or for leucine, pantothenate, and methionine. These triple auxotrophic strains retained their acid-fastness, their ability to generate both a drug persistence phenotype and drug-resistant mutants, and their susceptibility to plaque-forming mycobacterial phages. MDR triple auxotrophic mutants were obtained in a two-step fashion, selecting first for solely isoniazid-resistant or rifampin-resistant mutants. Interestingly, selection for isoniazid-resistant mutants of the methionine auxotroph generated isolates with single point mutations in
katG
, which encodes an isoniazid-activating enzyme, whereas similar selection using the arginine auxotroph yielded isoniazid-resistant mutants with large deletions in the chromosomal region containing
katG
. These
M. tuberculosis
MDR strains were readily sterilized by second-line tuberculosis drugs and failed to kill immunocompromised mice. These strains provide attractive candidates for
M. tuberculosis
biology studies and drug screening outside the BSL3 facility.
IMPORTANCE
Elimination of
Mycobacterium tuberculosis
, the bacterium causing tuberculosis, requires enhanced understanding of its biology in order to identify new drugs against drug-susceptible and drug-resistant
M. tuberculosis
as well as uncovering novel pathways that lead to
M. tuberculosis
death. To circumvent the need for a biosafety level 3 (BSL3) laboratory when conducting research on
M. tuberculosis
, we have generated drug-susceptible and drug-resistant triple auxotrophic strains of
M. tuberculosis
suitable for use in a BSL2 laboratory. These strains originate from a double auxotrophic
M. tuberculosis
strain, H37Rv Δ
panCD
Δ
leuCD
, which was reclassified as a BSL2 strain based on its lack of lethality in immunocompromised and immunocompetent mice. A third auxotrophy (methionine or arginine) was introduced via deletion of
metA
or
argB
, respectively, since
M. tuberculosis
Δ
metA
and
M. tuberculosis
Δ
argB
are unable to survive amino acid auxotrophy and infect their host. The resulting triple auxotrophic
M. tuberculosis
strains retained characteristics of
M. tuberculosis
relevant for most types of investigations.
Funder
HHS | NIH | National Institute of Allergy and Infectious Diseases
Stony Wold-Herbert Fund
Potts Family Foundation
Publisher
American Society for Microbiology
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献